T1	PROC 45 82	Estudio de la eficacia y la seguridad
T2	DISO 118 137	enfermedad de Crohn
#1	AnnotatorNotes T2	C0010346; Crohn Disease; Disease or Syndrome
T3	PROC 193 317	Protocolo multicéntrico en fase II/III aleatorizado, con doble enmascaramiento, de grupos paralelos y controlado con placebo
T4	CHEM 384 394	guselkumab
#2	AnnotatorNotes T4	C3852217; guselkumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	CHEM 324 340	principio activo
#3	AnnotatorNotes T5	C1372955; Active ingredient; Chemical Viewed Functionally
T6	PROC 346 380	evaluar la eficacia y la seguridad
#4	AnnotatorNotes T6	C0511730; Identify product efficacy and safety issues; Health Care Activity
T7	DISO 416 435	enfermedad de Crohn
#5	AnnotatorNotes T7	C0010346; Crohn Disease; Disease or Syndrome
T8	DISO 492 526	Enfermedad inflamatoria intestinal
#6	AnnotatorNotes T8	C0021390; Inflammatory Bowel Diseases; Disease or Syndrome
T9	DISO 528 531	EII
#7	AnnotatorNotes T9	C0021390; Inflammatory Bowel Diseases; Disease or Syndrome
T10	DISO 558 577	Enfermedad de Crohn
#8	AnnotatorNotes T10	C0010346; Crohn Disease; Disease or Syndrome
T11	DISO 645 664	enfermedad de Crohn
#9	AnnotatorNotes T11	C0010346; Crohn Disease; Disease or Syndrome
T12	DISO 667 699	enfermedad de Crohn fistulizante
#10	AnnotatorNotes T12	C3888864; Fistulising Crohn's disease; Disease or Syndrome
T13	DISO 777 784	colitis
#11	AnnotatorNotes T13	C0009319; Colitis; Disease or Syndrome
T14	DISO 786 793	ileítis
#12	AnnotatorNotes T14	C0020877; Ileitis; Disease or Syndrome
T15	DISO 796 807	ileocolitis
#13	AnnotatorNotes T15	C0949272; IIeocolitis; Disease or Syndrome
T16	PROC 1466 1477	Diagnóstico
#14	AnnotatorNotes T16	C0011900; Diagnosis; Diagnostic Procedure
T17	PROC 861 872	radiografía
#15	AnnotatorNotes T17	C1306645; Plain x-ray; Diagnostic Procedure | C1962945; Radiographic imaging procedure; Diagnostic Procedure
T18	PROC 887 897	endoscopia
#16	AnnotatorNotes T18	C0014245; Endoscopy (procedure); Diagnostic Procedure
T19	DISO 906 925	enfermedad de Crohn
#17	AnnotatorNotes T19	C0010346; Crohn Disease; Disease or Syndrome
T20	DISO 1029 1044	dolor abdominal
#18	AnnotatorNotes T20	C0000737; Abdominal Pain; Sign or Symptom
T21	PROC 1376 1412	tratamiento convencional o biológico
T22	PROC 1165 1174	protocolo
#19	AnnotatorNotes T22	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T23	PROC 1267 1294	prueba de embarazo en orina
#20	AnnotatorNotes T23	C0430056; Urine pregnancy test; Laboratory Procedure
T24	DISO 1419 1438	enfermedad de Crohn
#21	AnnotatorNotes T24	C0010346; Crohn Disease; Disease or Syndrome
T25	DISO 1488 1504	colitis ulcerosa
#22	AnnotatorNotes T25	C0009324; Ulcerative Colitis; Disease or Syndrome
T26	DISO 1507 1528	colitis indeterminada
#23	AnnotatorNotes T26	C0341332; Indeterminate colitis; Disease or Syndrome
T27	DISO 1537 1577	complicaciones de la enfermedad de Crohn
T28	DISO 1602 1624	estenosis sintomáticos
T29	DISO 1626 1654	síndrome del intestino corto
#24	AnnotatorNotes T29	C0036992; Short Bowel Syndrome; Disease or Syndrome
T30	DISO 1672 1685	manifestación
#25	AnnotatorNotes T30	C0037088; Signs and Symptoms; Sign or Symptom
T31	CHEM 1708 1718	medicación
#26	AnnotatorNotes T31	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T32	DISO 1740 1759	enfermedad de Crohn
#27	AnnotatorNotes T32	C0010346; Crohn Disease; Disease or Syndrome
T33	CHEM 1772 1790	agentes biológicos
#28	AnnotatorNotes T33	C0005515; Biological Factors; Biologically Active Substance
T34	DISO 1809 1828	enfermedad de Crohn
#29	AnnotatorNotes T34	C0010346; Crohn Disease; Disease or Syndrome
T35	CHEM 1830 1850	fármaco experimental
#30	AnnotatorNotes T35	C0304229; Experimental drug; Pharmacologic Substance
T36	PROC 1934 1943	protocolo
#31	AnnotatorNotes T36	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T37	CHEM 1966 1981	inhibidores p40
T38	CHEM 1984 1999	inhibidores p19
T39	CHEM 86 96	guselkumab
#32	AnnotatorNotes T39	C3852217; guselkumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T40	ANAT 516 526	intestinal
#33	AnnotatorNotes T40	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T41	PROC 874 884	histología
#34	AnnotatorNotes T41	C0344441; Histology Procedure; Laboratory Procedure
T42	ANAT 1035 1044	abdominal
#35	AnnotatorNotes T42	C0000726; Abdomen; Body Location or Region | C1281594; Entire abdomen; Body Part, Organ, or Organ Component
T43	PROC 1085 1103	pruebas analíticas
T44	ANAT 1289 1294	orina
#36	AnnotatorNotes T44	C0042036; Urine; Body Substance
T45	DISO 1326 1338	Intolerancia
#37	AnnotatorNotes T45	C0277585; Intolerance to drug; Pathologic Function
T46	DISO 1584 1599	estrechamientos
#38	AnnotatorNotes T46	C3854333; Narrowing; Anatomical Abnormality
T47	ANAT 1639 1648	intestino
#39	AnnotatorNotes T47	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T48	PROC 1853 1867	procedimientos
#40	AnnotatorNotes T48	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T49	Date 13 17	2017
T50	Duration 703 719	al menos 3 meses
T51	Duration 747 770	un mínimo de 12 semanas
T52	Date 823 851	cualquier momento del pasado
T54	LIVB 1181 1188	mujeres
#41	AnnotatorNotes T54	C0043210; Woman; Population Group
T55	PHYS 1207 1228	capacidad de concebir
#42	AnnotatorNotes T55	C3831118; Childbearing Potential; Clinical Attribute
T56	Neg_cue 1252 1260	negativo
T58	Date 1478 1484	actual
T60	PHYS 1277 1285	embarazo
#43	AnnotatorNotes T60	C0032961; Pregnancy; Organism Function
T61	LIVB 100 113	participantes
#44	AnnotatorNotes T61	C4554048; Study Participant; Population Group
T62	LIVB 398 411	participantes
#45	AnnotatorNotes T62	C4554048; Study Participant; Population Group
T53	PHYS 1009 1021	deposiciones
#46	AnnotatorNotes T53	C0011135; Defecation; Organism Function
T57	Dose 1688 1704	Dosis inestables
A1	Assertion T60 Negated
A2	Status T45 History_of
A3	Status T37 History_of
A4	Status T38 History_of
A5	Status T17 History_of
A6	Status T41 History_of
A7	Status T18 History_of
#47	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity
#48	AnnotatorNotes T3	C1096776; Multicenter Study; Research Activity + C1519042; Phase II/III Trial; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C2826345; Parallel Study; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product 
#49	AnnotatorNotes T21	C2945704; Conventional Treatment; Therapeutic or Preventive Procedure + C1531518; Biological treatment; Therapeutic or Preventive Procedure
#50	AnnotatorNotes T58	C0521116; Current (present time); Temporal Concept 
#51	AnnotatorNotes T52	C1444637; In the past; Temporal Concept
T59	Neg_cue 2040 2046	impida
T63	Observation 2050 2077	participación en el estudio
A8	Assertion T63 Negated
#52	AnnotatorNotes T63	C1278516; Patient participation status; Finding (?)
R1	Negation Arg1:T59 Arg2:T63	
R2	Negation Arg1:T56 Arg2:T60	
T64	Observation 2012 2035	contraindicación médica
#53	AnnotatorNotes T64	C1301624; Medical contraindication; Finding
R3	Before Arg1:T64 Arg2:T63	
R4	Experiences Arg1:T61 Arg2:T39	
R5	Experiences Arg1:T61 Arg2:T2	
T65	Quantifier_or_Qualifier 141 171	moderada a intensamente activa
#54	AnnotatorNotes T65	C1299393; Moderate to severe; Qualitative Concept + C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
T66	Quantifier_or_Qualifier 439 469	moderada a intensamente activa
#55	AnnotatorNotes T66	C1299393; Moderate to severe; Qualitative Concept + C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
T67	Quantifier_or_Qualifier 581 611	moderada a intensamente activa
#56	AnnotatorNotes T67	C1299393; Moderate to severe; Qualitative Concept + C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
T68	Quantifier_or_Qualifier 929 959	moderada a intensamente activa
#57	AnnotatorNotes T68	C1299393; Moderate to severe; Qualitative Concept + C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R6	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T68	
R7	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T67	
R8	Has_Duration_or_Interval Arg1:T11 Arg2:T50	
R9	Has_Duration_or_Interval Arg1:T12 Arg2:T50	
R10	Location_of Arg1:T40 Arg2:T8	
R11	Location_of Arg1:T40 Arg2:T9	
R12	Has_Quantifier_or_Qualifier Arg1:T2 Arg2:T65	
R13	Experiences Arg1:T62 Arg2:T4	
R14	Has_Quantifier_or_Qualifier Arg1:T62 Arg2:T7	
R15	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T66	
R16	Experiences Arg1:T62 Arg2:T5	
R17	Has_Duration_or_Interval Arg1:T12 Arg2:T51	
R18	Has_Duration_or_Interval Arg1:T11 Arg2:T51	
R19	Causes Arg1:T11 Arg2:T13	
R20	Causes Arg1:T11 Arg2:T14	
R21	Causes Arg1:T11 Arg2:T15	
R22	Causes Arg1:T12 Arg2:T13	
R23	Causes Arg1:T12 Arg2:T14	
R24	Causes Arg1:T12 Arg2:T15	
R25	Overlap Arg1:T17 Arg2:T52	
R26	Overlap Arg1:T41 Arg2:T52	
R27	Overlap Arg1:T18 Arg2:T52	
T69	PROC 989 993	CDAI
#58	AnnotatorNotes T69	C5566328; Assessment using Crohn's Disease Activity Index; Health Care Activity
T70	Observation 995 1021	Frecuencia de deposiciones
#59	AnnotatorNotes T70	C0426642; Frequency of bowel action; Finding
R34	Location_of Arg1:T42 Arg2:T20	
T71	PROC 1052 1058	SES-CD
#60	AnnotatorNotes T71	C5549856; Assessment using Simple Endoscopic Score for Crohn's Disease; Health Care Activity
#61	AnnotatorNotes T43	C4505475; Clinical Laboratory Testings; Laboratory Procedure | C4505474; Clinical Laboratory Tests; Laboratory Procedure
T72	PROC 1110 1119	selección
#62	AnnotatorNotes T72	C0242802; Patient Selection; Research Activity
R40	Overlap Arg1:T43 Arg2:T72	
T73	Result_or_Value 1120 1144	dentro de los parámetros
R41	Has_Result_or_Value Arg1:T43 Arg2:T73	
R42	Experiences Arg1:T54 Arg2:T55	
R43	Experiences Arg1:T54 Arg2:T23	
R44	Location_of Arg1:T44 Arg2:T23	
R45	Experiences Arg1:T54 Arg2:T60	
T74	PROC 1301 1310	selección
#63	AnnotatorNotes T74	C0242802; Patient Selection; Research Activity
R46	Overlap Arg1:T23 Arg2:T74	
T75	CONC 1316 1322	inicio
#64	AnnotatorNotes T75	C4684789; Study Start; Temporal Concept | C2349982; Study start time; Temporal Concept
R47	Overlap Arg1:T23 Arg2:T75	
R48	Causes Arg1:T21 Arg2:T45	
T76	Observation 1352 1372	respuesta inadecuada
#65	AnnotatorNotes T76	C0858218; Inappropriate drug response; Finding
R49	Overlap Arg1:T76 Arg2:T21	
R50	Overlap Arg1:T16 Arg2:T58	
R51	Overlap Arg1:T25 Arg2:T58	
R52	Overlap Arg1:T26 Arg2:T58	
#66	AnnotatorNotes T27	C4040843; Complication due to Crohn's disease; Pathologic Function
R53	Location_of Arg1:T47 Arg2:T29	
R54	Has_Dose_or_Strength Arg1:T31 Arg2:T57	
T77	Quantifier_or_Qualifier 1719 1731	concomitante
#67	AnnotatorNotes T77	C0521115; Simultaneous; Temporal Concept
R55	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T77	
T78	CONC 1868 1905	fuera del período de tiempo permitido
R56	Overlap Arg1:T48 Arg2:T78	
R57	Overlap Arg1:T35 Arg2:T78	
R58	Overlap Arg1:T33 Arg2:T78	
R28	Overlap Arg1:T45 Arg2:T24	
A9	Experiencer T61 Patient
A10	Experiencer T62 Patient
A11	Experiencer T54 Patient
T79	Result_or_Value 1242 1260	resultado negativo
R29	Has_Result_or_Value Arg1:T23 Arg2:T79	
